241 related articles for article (PubMed ID: 22789711)
21. Construction of triple-transfected cells [organic anion-transporting polypeptide (OATP) 1B1/multidrug resistance-associated protein (MRP) 2/MRP3 and OATP1B1/MRP2/MRP4] for analysis of the sinusoidal function of MRP3 and MRP4.
Hirouchi M; Kusuhara H; Onuki R; Ogilvie BW; Parkinson A; Sugiyama Y
Drug Metab Dispos; 2009 Oct; 37(10):2103-11. PubMed ID: 19628752
[TBL] [Abstract][Full Text] [Related]
22. Contribution of organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 to hepatic uptake of nateglinide, and the prediction of drug-drug interactions via these transporters.
Takanohashi T; Kubo S; Arisaka H; Shinkai K; Ubukata K
J Pharm Pharmacol; 2012 Feb; 64(2):199-206. PubMed ID: 22221095
[TBL] [Abstract][Full Text] [Related]
23. Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes.
De Bruyn T; Ye ZW; Peeters A; Sahi J; Baes M; Augustijns PF; Annaert PP
Eur J Pharm Sci; 2011 Jul; 43(4):297-307. PubMed ID: 21605667
[TBL] [Abstract][Full Text] [Related]
24. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins.
Salphati L; Chu X; Chen L; Prasad B; Dallas S; Evers R; Mamaril-Fishman D; Geier EG; Kehler J; Kunta J; Mezler M; Laplanche L; Pang J; Rode A; Soars MG; Unadkat JD; van Waterschoot RA; Yabut J; Schinkel AH; Scheer N
Drug Metab Dispos; 2014 Aug; 42(8):1301-13. PubMed ID: 24855184
[TBL] [Abstract][Full Text] [Related]
26. Interaction of digitalis-like compounds with liver uptake transporters NTCP, OATP1B1, and OATP1B3.
Gozalpour E; Greupink R; Wortelboer HM; Bilos A; Schreurs M; Russel FG; Koenderink JB
Mol Pharm; 2014 Jun; 11(6):1844-55. PubMed ID: 24754247
[TBL] [Abstract][Full Text] [Related]
27. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.
Noé J; Portmann R; Brun ME; Funk C
Drug Metab Dispos; 2007 Aug; 35(8):1308-14. PubMed ID: 17470528
[TBL] [Abstract][Full Text] [Related]
28. Comparative study of culture conditions for maintaining CYP3A4 and ATP-binding cassette transporters activity in primary cultured human hepatocytes.
Takeba Y; Matsumoto N; Takenoshita-Nakaya S; Harimoto Y; Kumai T; Kinoshita Y; Nakano H; Ohtsubo T; Kobayashi S
J Pharmacol Sci; 2011; 115(4):516-24. PubMed ID: 21436605
[TBL] [Abstract][Full Text] [Related]
29. Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies.
Jossé R; Aninat C; Glaise D; Dumont J; Fessard V; Morel F; Poul JM; Guguen-Guillouzo C; Guillouzo A
Drug Metab Dispos; 2008 Jun; 36(6):1111-8. PubMed ID: 18347083
[TBL] [Abstract][Full Text] [Related]
30. Hepatic uptake and excretion of (-)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a novel if channel inhibitor, in rats and humans.
Umehara K; Iwai M; Adachi Y; Iwatsubo T; Usui T; Kamimura H
Drug Metab Dispos; 2008 Jun; 36(6):1030-8. PubMed ID: 18332079
[TBL] [Abstract][Full Text] [Related]
31. Three-dimensional HepaRG model as an attractive tool for toxicity testing.
Leite SB; Wilk-Zasadna I; Zaldivar JM; Airola E; Reis-Fernandes MA; Mennecozzi M; Guguen-Guillouzo C; Chesne C; Guillou C; Alves PM; Coecke S
Toxicol Sci; 2012 Nov; 130(1):106-16. PubMed ID: 22843569
[TBL] [Abstract][Full Text] [Related]
32. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.
Yamashiro W; Maeda K; Hirouchi M; Adachi Y; Hu Z; Sugiyama Y
Drug Metab Dispos; 2006 Jul; 34(7):1247-54. PubMed ID: 16624871
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of hepatic uptake transporters by flavonoids.
Mandery K; Balk B; Bujok K; Schmidt I; Fromm MF; Glaeser H
Eur J Pharm Sci; 2012 May; 46(1-2):79-85. PubMed ID: 22394605
[TBL] [Abstract][Full Text] [Related]
34. A two-dimensional multiwell cell culture method for the production of CYP3A4-expressing hepatocyte-like cells from HepaRG cells.
Ooeda K; Kubiura-Ichimaru M; Tsuji S; Okuyama S; Yamashita M; Mine A; Kawamura F; Ueyama T; Tada M
Pharmacol Res Perspect; 2020 Oct; 8(5):e00652. PubMed ID: 32955797
[TBL] [Abstract][Full Text] [Related]
35. Substrate-dependent inhibition of organic anion transporting polypeptide 1B1: comparative analysis with prototypical probe substrates estradiol-17β-glucuronide, estrone-3-sulfate, and sulfobromophthalein.
Izumi S; Nozaki Y; Komori T; Maeda K; Takenaka O; Kusano K; Yoshimura T; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2013 Oct; 41(10):1859-66. PubMed ID: 23920221
[TBL] [Abstract][Full Text] [Related]
36. Mechanistic In Vitro Studies Indicate that the Clinical Drug-Drug Interaction between Telithromycin and Simvastatin Acid Is Driven by Time-Dependent Inhibition of CYP3A4 with Minimal Effect on OATP1B1.
Elsby R; Hare V; Neal H; Outteridge S; Pearson C; Plant K; Gill RU; Butler P; Riley RJ
Drug Metab Dispos; 2019 Jan; 47(1):1-8. PubMed ID: 30348903
[TBL] [Abstract][Full Text] [Related]
37. Serum-free culture of primary human hepatocytes in a miniaturized hollow-fibre membrane bioreactor for pharmacological in vitro studies.
Lübberstedt M; Müller-Vieira U; Biemel KM; Darnell M; Hoffmann SA; Knöspel F; Wönne EC; Knobeloch D; Nüssler AK; Gerlach JC; Andersson TB; Zeilinger K
J Tissue Eng Regen Med; 2015 Sep; 9(9):1017-26. PubMed ID: 23165723
[TBL] [Abstract][Full Text] [Related]
38. Cytochrome P450-dependent metabolism in HepaRG cells cultured in a dynamic three-dimensional bioreactor.
Darnell M; Schreiter T; Zeilinger K; Urbaniak T; Söderdahl T; Rossberg I; Dillnér B; Berg AL; Gerlach JC; Andersson TB
Drug Metab Dispos; 2011 Jul; 39(7):1131-8. PubMed ID: 21436404
[TBL] [Abstract][Full Text] [Related]
39. Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin.
Varma MV; Lin J; Bi YA; Rotter CJ; Fahmi OA; Lam JL; El-Kattan AF; Goosen TC; Lai Y
Drug Metab Dispos; 2013 May; 41(5):966-74. PubMed ID: 23393219
[TBL] [Abstract][Full Text] [Related]
40. The eighth and ninth transmembrane domains in organic anion transporting polypeptide 1B1 affect the transport kinetics of estrone-3-sulfate and estradiol-17beta-D-glucuronide.
Miyagawa M; Maeda K; Aoyama A; Sugiyama Y
J Pharmacol Exp Ther; 2009 May; 329(2):551-7. PubMed ID: 19244099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
